Replies to post #217 on CardioGenesis Corp (fka CGCP)

[Golden Cross]

CGCP Cardiogenesis Announces Publication on Holmium:YAG TMR System in Prominent Scientific Journal
PR Newswire - March 7, 2006 7:31 AM (EDT)

Article Highlights Company's Advanced Minimally Invasive System, Potential When Combined with Biologic/Pharmacologic Agents

FOOTHILL RANCH, Calif., March 7, 2006 /PRNewswire-FirstCall via COMTEX/ -- Cardiogenesis Corporation (OTC Bulletin Board: CGCP), the market leader in surgical products and accessories used in angina-relieving Transmyocardial Revascularization (TMR) and Percutaneous Myocardial Channeling (PMC) procedures, announced today the publication of an Expert Review of Medical Devices focused on the Company's Holmium:YAG TMR system in the March edition of Future Drugs.

Future Drugs is a scientific publication based in the UK that provides healthcare practitioners and research professionals with objective cutting-edge information on exciting emerging trends in healthcare and advances in the major therapeutic areas through the Expert Review series.

Chairman and CEO, Michael J. Quinn commented on this prominent publication. "It is noteworthy to see recognition of the increasing clinical importance of the TMR therapy in a cutting edge scientific journal. This is a reflection of the substantial published body of evidence supporting the clinical significance of our Holmium:YAG TMR system, and our efforts in advancing the technology to improve patient outcomes. We are now completing the IDE feasibility trials with our minimally invasive PEARL surgical delivery systems, and have initiated our preliminary safety and feasibility trial with our advanced PHOENIX Revascularization Delivery System for the precise targeted delivery of biologic or pharmacologic materials to the Holmium:YAG thermoacoustic stimulated tissue zone surrounding our TMR channels."

The Expert Review article "Holmium:YAG laser system for transmyocardial revascularization" is authored by Keith B. Allen, MD of the Heart Center of Indiana. In his discussion of mechanism of action, the author highlights the more than 20 peer reviewed works published from researchers at Duke University Medical Center. He states, "Angiogenesis is the most likely mechanism of action responsible for clinical improvement following TMR, and research should be continued to find ways to augment this process."

Mr. Quinn stated, "We are taking the important next steps with TMR to increase its physiologic and clinical impact. Reducing the surgical injury required in delivering this powerful therapy with our minimally invasive PEARL Robotic and Thoracoscopic delivery systems is an important platform improvement. We are now leveraging our understanding of the thermoacoustic stimulated tissue zone created by our Holmium:YAG fiberoptic delivery system for the delivery of potent therapeutic agents to generate an even greater response. The PHOENIX combination delivery system provides the precise and targeted delivery of biologic or pharmacologic therapeutic agents directly into and around the thermoacoustic stimulated tissue zone."

In the Future Drugs article, the author cited the improved Kaplan Meier survival at 5 years achieved with the Cardiogenesis Holmium:YAG system (Annals of Thoracic Surgery. 78, 458-65 (2004)). Dr. Allen stated in his remarks, "Considering the increased operative and long term cardiac risks predicted by incomplete revascularization and the documented operative and long term benefits associated with adjunctive TMR in randomized patients with diffuse CAD, increased utilization of this therapy is warranted. In parallel, it is imperative that research continues into identifying growth factor, therapeutic or stem cell-based materials, which when coadministered may enhance these positive outcomes."

Mr. Quinn concluded, "We strongly agree with Dr. Allen's conclusion that the published results of TMR as a primary and secondary therapy supports increased utilization of TMR in the treatment of diffuse coronary artery disease. We are also focused on advancing the technology to make available our minimally invasive PEARL delivery systems and the PHOENIX combination delivery system to optimize patient outcomes."